Lilly signs licensing deal with Mediar for IPF drug
Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...
Contract Pharma22h
Mediar, Lilly Enter Global Licensing Agreement for WISP1 Antibody
A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.